相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abdominal aortic calcification and the risk of bone fractures: a meta-analysis of prospective cohort studies
Dailin Wei et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2018)
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
GSK-3β inhibition suppresses instability-induced osteolysis by a dual action on osteoblast and osteoclast differentiation
Mehdi Amirhosseini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know
Pierre Delanaye et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
The Effects of Systemic Therapy of PEGylated NEL-Like Protein 1 (NELL-1) on Fracture Healing in Mice
Justine Tanjaya et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Sclerostin deficiency modifies the development of CKD-MBD in mice
Nadine Kaesler et al.
BONE (2018)
Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists
Gill Holdsworth et al.
BONE (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture
Chor-Wing Sing et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases
Luc Rochette et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease
Cong Zeng et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis
Xiaodong Li et al.
ENDOCRINOLOGY (2018)
Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis
Smriti Murali Krishna et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Systematic review and meta-analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women
Yiyun Zhang et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2017)
Abaloparatide Is an Anabolic, but Does It Spare Resorption?
T. John Martin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism
Elena Tsourdi et al.
ENDOCRINOLOGY (2017)
Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study
Hua Zhou et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2017)
Osteoporosis and ischemic cardiovascular disease
Michel Laroche et al.
JOINT BONE SPINE (2017)
New Insights Into the Local and Systemic Functions of Sclerostin: Regulation of Quiescent Bone Lining Cells and Beige Adipogenesis in Peripheral Fat Depots
Jesus Delgado-Calle et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis
Nicola Veronese et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts
Sang Wan Kim et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
Francis H. Glorieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots
Keertik Fulzele et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
Lothar Seefried et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
The Utility of Biomarkers in Osteoporosis Management
Patrick Garnero
MOLECULAR DIAGNOSIS & THERAPY (2017)
Romosozumab - on track or derailed?
Sundeep Khosla
NATURE REVIEWS ENDOCRINOLOGY (2017)
Romosozumab - Promising or Practice Changing?
Clifford J. Rosen
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures
N. C. W. Harvey et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)
Jacquelin Jolette et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2017)
Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma
Y. Wang et al.
BLOOD CANCER JOURNAL (2017)
Ultraviolet B Exposure Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice by Expanding CD4+Foxp3+ Regulatory T Cells
Tomohiro Hayashi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Osteoporosis treatment: recent developments and ongoing challenges
Sundeep Khosla et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G. Bone et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Using Osteoporosis Therapies in Combination
Michael R. McClung
CURRENT OSTEOPOROSIS REPORTS (2017)
Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD
Geert J. Behets et al.
PLOS ONE (2017)
Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based metaanalysis involving 26,442 participants
Lena Tschiderer et al.
PLOS ONE (2017)
Use of an Osteoblast Overload Damage Model to Probe the Effect of Icariin on the Proliferation, Differentiation and Mineralization of MC3T3-E1 Cells through the Wnt/β-Catenin Signalling Pathway
Yingjie Liu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Sirtuin 6, a possible therapeutic target for type 2 diabetes
Eun Ju Bae
ARCHIVES OF PHARMACAL RESEARCH (2017)
Sirtuins at the crossroads of stemness, aging, and cancer
Carol O'Callaghan et al.
AGING CELL (2017)
Nuclear sirtuins and inflammatory signaling pathways
Keila Lopes Mendes et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Deletion of NF-κB/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation
Talha Ijaz et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Wnt signaling in cardiovascular disease: opportunities and challenges
Austin Gay et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Neural EGF-like protein 1 (NELL-1): Signaling crosstalk in mesenchymal stem cells and applications in regenerative medicine
Mikhail Pakvasa et al.
GENES & DISEASES (2017)
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
Carolina A. Moreira et al.
BONE (2017)
Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys
Rogely Waite Boyce et al.
BONE (2017)
NELL-1 induces Sca-1+ mesenchymal progenitor cell expansion in models of bone maintenance and repair
Aaron W. James et al.
JCI INSIGHT (2017)
Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho
Shunsuke Yamada et al.
BONE (2017)
The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology
Keith A. Hruska et al.
BONE (2017)
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
Michelle M. McDonald et al.
BLOOD (2017)
Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide
Roger Zebaze et al.
BONE (2017)
Wnt signaling in the vessel wall
Lina Badimon et al.
CURRENT OPINION IN HEMATOLOGY (2017)
Deletion of hypoxia-inducible factor-1α in myeloid lineage exaggerates angiotensin II-induced formation of abdominal aortic aneurysm
Yusuke Takahara et al.
CLINICAL SCIENCE (2017)
Sclerostin deficiency in humans
Antoon H. van Lierop et al.
BONE (2017)
Effects of sclerostin antibodies in animal models of osteoporosis
Michael Stuart Ominsky et al.
BONE (2017)
TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms
Stoyan N. Angelov et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats
Yang Liu et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification
Lucie Henaut et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways
Megan M. Weivoda et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength
W. Yao et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm
Emina Vorkapic et al.
ATHEROSCLEROSIS (2016)
Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Guido Kranenburg et al.
ATHEROSCLEROSIS (2016)
Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model
Cristal S. Yee et al.
BONE (2016)
Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice
Carlos Tarin et al.
CARDIOVASCULAR RESEARCH (2016)
D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization
Nicolas H. Pope et al.
FASEB JOURNAL (2016)
Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2016)
Anti-sclerostin - is there an indication?
Sune Larsson
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED (2016)
RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release
Colin Davenport et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice
Qiong Duan et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice
Kyoko Kohashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2016)
A Crisis in the Treatment of Osteoporosis
Sundeep Khosla et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap-/- Mice, a Model of Recessive Osteogenesis Imperfecta
Ingo Grafe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone
Igor Fijalkowski et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
J. N. Tsai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Calorie restriction protects against experimental abdominal aortic aneurysms in mice
Yue Liu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy
Qiaoli Li et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
The heart and vascular system in dialysis
Christoph Wanner et al.
LANCET (2016)
Romosozumab - getting there but not quite yet
Socrates E. Papapoulos
NATURE REVIEWS ENDOCRINOLOGY (2016)
Osteocytic signalling pathways as therapeutic targets for bone fragility
Lilian I. Plotkin et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
Building Better Bones with Biologics - A New Approach to Osteoporosis?
Clifford J. Rosen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PARATHYROID HORMONE-RELATED PROTEIN, ITS REGULATION OF CARTILAGE AND BONE DEVELOPMENT, AND ROLE IN TREATING BONE DISEASES
T. John Martin
PHYSIOLOGICAL REVIEWS (2016)
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study
Luc Chouinard et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2016)
Differentiation of Vascular Stem Cells Contributes to Ectopic Calcification of Atherosclerotic Plaque
Aleksandra Leszczynska et al.
STEM CELLS (2016)
Vertebral Implantation of NELL-1 Enhances Bone Formation in an Osteoporotic Sheep Model
Aaron W. James et al.
TISSUE ENGINEERING PART A (2016)
Antiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/β-catenin pathway
Guangming Chen et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
Bente Langdahl et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2016)
In Search of New Therapeutic Targets in Obesity Treatment: Sirtuins
Alina Kurylowicz
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration
Jin Hee Kwak et al.
BIOMATERIALS (2015)
Abdominal aortic calcification and risk of fracture among older women - The SOF study
Pawel Szulc et al.
BONE (2015)
Rapidly growing Brtl/ plus mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment
Benjamin P. Sinder et al.
BONE (2015)
Anti-DKK1 antibody promotes bone fracture healing through activation of β-catenin signaling
Hongting Jin et al.
BONE (2015)
Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis
Christian Graeff et al.
BONE (2015)
Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia
Zahra Achiou et al.
BONE (2015)
LRP4 in neuromuscular junction and bone development and diseases
Chengyong Shen et al.
BONE (2015)
Stimulation of Wnt/beta-Catenin Signaling to Improve Bone Development by Naringin via Interacting with AMPK and Akt
Dawei Wang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Omega 3 Polyunsaturated Fatty Acids Suppress the Development of Aortic Aneurysms Through the Inhibition of Macrophage-Mediated Inflammation
Takuma Yoshihara et al.
CIRCULATION JOURNAL (2015)
Vascular Smooth Muscle LRP6 Limits Arteriosclerotic Calcification in Diabetic LDLR-/- Mice by Restraining Noncanonical Wnt Signals
Su-Li Cheng et al.
CIRCULATION RESEARCH (2015)
Soybean isoflavone treatment induces osteoblast differentiation and proliferation by regulating analysis of Wnt/β-catenin pathway
Fang Yu et al.
GENE (2015)
Systemic Administration of Sclerostin Antibody Enhances Bone Morphogenetic Protein-Induced Femoral Defect Repair in a Rat Model
Brian A. Tinsley et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2015)
Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy
Sharon M. Moe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density
Christopher P. Recknor et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Association Between Bisphosphonates Therapy and Incident Myocardial Infarction: Meta-analysis and Trial Sequential Analysis
Bao-tao Huang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2015)
LRP5 deficiency down-regulates Wnt signalling and promotes aortic lipid infiltration in hypercholesterolaemic mice
Maria Borrell-Pages et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients
P. Evenepoel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Sclerostin and DKK1: new players in renal bone and vascular disease
Pieter Evenepoel et al.
KIDNEY INTERNATIONAL (2015)
Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification
Abdul Rashid Qureshi et al.
KIDNEY INTERNATIONAL (2015)
Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption
Lei Xiong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
NELL-1 in the treatment of osteoporotic bone loss
Aaron W. James et al.
NATURE COMMUNICATIONS (2015)
Sclerostin and CKD-MBD
Susan C. Schiavi
CURRENT OSTEOPOROSIS REPORTS (2015)
Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm
Huimin Yan et al.
ACTA PHARMACEUTICA SINICA B (2015)
Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study
Joy N. Tsai et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study
Christiane Drechsler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Preclinical Toxicity of AZD7969: Effects of GSK3β Inhibition in Adult Stem Cells
A. P. Hall et al.
TOXICOLOGIC PATHOLOGY (2015)
Osteoprotegerin Deficiency Limits Angiotensin II-Induced Aortic Dilatation and Rupture in the Apolipoprotein E-Knockout Mouse
Corey S. Moran et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Cholesterol modulates LRP5 expression in the vessel wall
M. Borrell-Pages et al.
ATHEROSCLEROSIS (2014)
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats
Marina Stolina et al.
BONE (2014)
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Swaminathan P. Iyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The Sirtuin1 Activator SRT3025 Down-Regulates Sclerostin and Rescues Ovariectomy-Induced Bone Loss and Biomechanical Deterioration in Female Mice
Hanna Artsi et al.
ENDOCRINOLOGY (2014)
Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
Xiaodong Li et al.
ENDOCRINOLOGY (2014)
Single-and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women
Juliet McColm et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Bone Matrix Quality After Sclerostin Antibody Treatment
Ryan D. Ross et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Severe Abdominal Aortic Calcification in Older Men Is Negatively Associated With DKK1 Serum Levels: The STRAMBO Study
P. Szulc et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients
Mehmet Kanbay et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
The Relationships Between Serum Sclerostin, Bone Mineral Density, and Vascular Calcification in Rheumatoid Arthritis
J. Paccou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Renal Elimination of Sclerostin Increases With Declining Kidney Function
Daniel Cejka et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Multiple Doses of Sclerostin Antibody Romosozumab in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled Study
Desmond Padhi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKD-Mineral and Bone Disorder
Yifu Fang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Can we safely target the WNT pathway?
Michael Kahn
NATURE REVIEWS DRUG DISCOVERY (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength
B. P. Sinder et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels
Ming-Kang Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Dkk1 and Msx2-Wnt7b Signaling Reciprocally Regulate the Endothelial-Mesenchymal Transition in Aortic Endothelial Cells
Su-Li Cheng et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women
Geeta Hampson et al.
BONE (2013)
Effects of PTH on osteocyte function
Teresita Bellido et al.
BONE (2013)
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
Samantha Pozzi et al.
BONE (2013)
The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications
Katherine Wesseling-Perry et al.
BONE (2013)
Vascular Calcification: An Update on Mechanisms and Challenges in Treatment
Meiting Wu et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-B pathway
Shih-Hung Tsai et al.
CARDIOVASCULAR RESEARCH (2013)
Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels
Sonia Morales-Santana et al.
DIABETES CARE (2013)
The Osteocyte: An Endocrine Cell . . . and More
Sarah L. Dallas et al.
ENDOCRINE REVIEWS (2013)
Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers
Antoon H. van Lierop et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus
Christine Hamann et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Plasma Dickkopf1 (DKK1) Concentrations Negatively Associate with Atherosclerotic Calcified Plaque in African-Americans with Type 2 Diabetes
Thomas C. Register et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women
Claire Durosier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Age- and Menopause-Related Bone Loss Compromise Cortical and Trabecular Microstructure
Ego Seeman
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
WNT signaling in bone homeostasis and disease: from human mutations to treatments
Roland Baron et al.
NATURE MEDICINE (2013)
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
J. -H. Kang et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome
Rajendra Kedlaya et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
NELL-1 Injection Maintains Long-Bone Quantity and Quality in an Ovariectomy-Induced Osteoporotic Senile Rat Model
Jinny Kwak et al.
TISSUE ENGINEERING PART A (2013)
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study
Vincent M. Brandenburg et al.
BMC NEPHROLOGY (2013)
Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover
Maria P. Yavropoulou et al.
BONE (2012)
Acute Myocardial Infarction and Atherosclerosis of the Coronary Arteries in Patients Treated with Drugs Against Osteoporosis: Calcium in the Vessels and not the Bones?
Peter Vestergaard
CALCIFIED TISSUE INTERNATIONAL (2012)
Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper
J. Goldhahn et al.
CALCIFIED TISSUE INTERNATIONAL (2012)
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Hua Zhu Ke et al.
ENDOCRINE REVIEWS (2012)
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy
Yves Sabbagh et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Roland Baron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Arterial calcification and bone physiology: role of the bone-vascular axis
Bithika Thompson et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke
J. -H. Kang et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Sclerostin Antibody Treatment Enhances Bone Strength but Does Not Prevent Growth Retardation in Young Mice Treated With Dexamethasone
M. Marenzana et al.
ARTHRITIS AND RHEUMATISM (2011)
A new function of Nell-1 protein in repressing adipogenic differentiation
Aaron W. James et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
The Regulation of Valvular and Vascular Sclerosis by Osteogenic Morphogens
Kristina I. Bostroem et al.
CIRCULATION RESEARCH (2011)
Alendronate and Raloxifene Use Related to Cardiovascular Diseases: Differentiation by Different Dosing Regimens of Alendronate
Pei-Yu Lu et al.
CLINICAL THERAPEUTICS (2011)
Sirt1 Is a Regulator of Bone Mass and a Repressor of Sost Encoding for Sclerostin, a Bone Formation Inhibitor
Einav Cohen-Kfir et al.
ENDOCRINOLOGY (2011)
Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
Xiaodong Li et al.
ENDOCRINOLOGY (2011)
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Olivier Leupin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice
Gang-Qing Yao et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2011)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Dickkopf-1 Regulates Bone Formation in Young Growing Rodents and Upon Traumatic Injury
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Nell-1, a Key Functional Mediator of Runx2, Partially Rescues Calvarial Defects in Runx2+/- Mice
Xinli Zhang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Patients With Sclerosteosis and Disease Carriers: Human Models of the Effect of Sclerostin on Bone Turnover
Antoon H. van Lierop et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing and Improves Bone Density and Strength of Nonfractured Bones
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays
Melissa McNulty et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody
Helmut Glantschnig et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Nell-1 Protein Promotes Bone Formation in a Sheep Spinal Fusion Model
Ronald K. Siu et al.
TISSUE ENGINEERING PART A (2011)
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys
Sutada Lotinun et al.
BONE (2010)
The syndromic status of sclerosteosis and van Buchem disease
P. Beighton et al.
CLINICAL GENETICS (2010)
Genome-Wide Pleiotropy of Osteoporosis-Related Phenotypes: The Framingham Study
David Karasik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Two Doses of Sclerostin Antibody in Cynomolgus Monkeys Increases Bone Formation, Bone Mineral Density, and Bone Strength
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Inhibition of Sclerostin by Monoclonal Antibody Increases Bone Formation, Bone Mass, and Bone Strength in Aged Male Rats
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis)
Sammy Elmariah et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Proteomics Characterization of Extracellular Space Components in the Human Aorta
Athanasios Didangelos et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Delivery of Lyophilized Nell-1 in a Rat Spinal Fusion Model
Weiming Li et al.
TISSUE ENGINEERING PART A (2010)
Dickkopf-1 Enhances Inflammatory Interaction Between Platelets and Endothelial Cells and Shows Increased Expression in Atherosclerosis
Thor Ueland et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Osteoprotegerin, vascular calcification and atherosclerosis
Ann Van Campenhout et al.
ATHEROSCLEROSIS (2009)
The role of Dickkopf-1 in bone development, homeostasis, and disease
Joseph J. Pinzone et al.
BLOOD (2009)
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
Deborah J. Heath et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Sclerostin in Mineralized Matrices and van Buchem Disease
R. L. van Bezooijen et al.
JOURNAL OF DENTAL RESEARCH (2009)
Generalized arterial calcification of infancy: treatment with bisphosphonates
Kim A. Ramjan et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Pathogenesis of Vascular Calcification in the Chronic Kidney Disease Mineral Bone Disorder: The Links Between Bone and the Vasculature
Keith A. Hruska et al.
SEMINARS IN NEPHROLOGY (2009)
Regulation of endothelial cell cytoskeletal reorganization by a secreted frizzled-related protein-1 and frizzled 4-and frizzled 7-dependent pathway
Pascale Dufourcq et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Bisphosphonates: how do they work?
Socrates E. Papapoulos
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Vascular calcification - Pathobiology of a multifaceted disease
Linda L. Demer et al.
CIRCULATION (2008)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity
R. Scott Pearsall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
S. Adami et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma
Z. Jin et al.
ONCOGENE (2007)
Chronic kidney disease - Effects on the cardiovascular system
Ernesto L. Schiffrin et al.
CIRCULATION (2007)
Beta-catenin signaling plays a disparate role in different phases of fracture repair: Implications for therapy to improve bone healing
Yan Chen et al.
PLOS MEDICINE (2007)
LRP6 mutation in a family with early coronary disease and metabolic risk factors
Arya Mani et al.
SCIENCE (2007)
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Shmuel Yaccoby et al.
BLOOD (2007)
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development
Rutger L. van Bezooijen et al.
DEVELOPMENTAL DYNAMICS (2007)
Vascular calcification and osteoporosis-from clinical observation towards molecular understanding
L. C. Hofbauer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation
Rutger L. van Bezooijen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
The osteoinductive properties of Nell-1 in a rat spinal fusion model
Steven S. Lu et al.
SPINE JOURNAL (2007)
Vascular calcification - Pathobiological mechanisms and clinical implications
Rebecca C. Johnson et al.
CIRCULATION RESEARCH (2006)
Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate
P. A. Price et al.
KIDNEY INTERNATIONAL (2006)
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia
Ji Li et al.
BONE (2006)
Nell-1-induced bone regeneration in calvarial defects
Tara Aghaloo et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Chronic kidney disease and mortality risk: A systematic review
Marcello Tonelli et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis
Constantinos Christodoulides et al.
JOURNAL OF CELL SCIENCE (2006)
Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass
Frederic Morvan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo
Nalini H. Kulkarni et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip
Y. Z. Bagger et al.
JOURNAL OF INTERNAL MEDICINE (2006)
Optical imaging of hydroxyapatite in the calcified vasculature of transgenic animals
A Zaheer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Bisphosphonate actions: Physical chemistry revisited
Socrates E. Papapoulos
BONE (2006)
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation
FC Caira et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE(-/-) mice
Brian J. Bennett et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice
P Clément-Lacroix et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Relationship between osteoporosis and cardiovascular disease in postmenopausal women
LB Tankó et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Usefulness of bone mineral density to predict significant coronary artery disease
PA Marcovitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Coronary calcification improves cardiovascular risk prediction in the elderly
R Vliegenthart et al.
CIRCULATION (2005)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Reduced relative risk of fractures among users of lithium
P Vestergaard et al.
CALCIFIED TISSUE INTERNATIONAL (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
RL van Bezooijen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Metacarpal cortical area and risk of coronary heart disease - The Framingham Study
EJ Samelson et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Aortic calcification and the risk of osteoporosis and fractures
E Schulz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway, controls vascular cell proliferation in vitro and in vivo
J Ezan et al.
CARDIOVASCULAR RESEARCH (2004)
Molecular, endocrine, and genetic mechanisms of arterial calcification
TM Doherty et al.
ENDOCRINE REVIEWS (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Comparison between measures of atherosclerosis and risk of stroke - The Rotterdam Study
M Hollander et al.
STROKE (2003)
Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads
TM Doherty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The natural history of sclerosteosis
H Hamersma et al.
CLINICAL GENETICS (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
K Staehling-Hampton et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
High bone density due to a mutation in LDL-receptor-related protein 5
LM Boyden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Stroke is associated with coronary calcification as detected by electron-beam CT - The Rotterdam Coronary Calcification Study
R Vliegenthart et al.
STROKE (2002)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait
RD Little et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse
M Mukhopadhyay et al.
DEVELOPMENTAL CELL (2001)
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption
PA Price et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study
DP Kiel et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
Bone mineral density in acute stroke patients - Low bone mineral density may predict first stroke in women
L Jorgensen et al.
STROKE (2001)
Rate of bone loss is associated with mortality in older women: A prospective study
DM Kado et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Progression of aortic calcification is associated with metacarpal bone loss during menopause - A population-based longitudinal study
AE Hak et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
分享论文
